Didanosine-Associated Retinal Toxicity in a Patient With a Mutation in the CRB1 Gene
- 10 November 2021
- journal article
- case report
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 6 (4) , 329-331
Abstract
This article describes a case of didanosine (DDI)-associated retinal toxicity in a patient with a heterozygous pathogenic variant in the CRB1 gene. Case report. A middle-aged patient with HIV controlled on HAART therapy, and a remote 10-year year history of treatment with DDI and tenofivir, presented with external ophthalmoplegia and well-circumscribed, midperipheral patterns of bilateral pigmentary retinopathy and chorioretinal atrophy in both eyes. Genetic testing revealed a heterozygous pathogenic variant in the CRB1 gene that encodes a protein (Crumbs homolog 1) involved in regulation of cell polarity and junctions and is localized adjacent to mitochondria in the ellipsoid and myoid area. This case highlights a potential role for genetic susceptibility to retinal toxicity in DDI-associated retinal toxicity. Large, prospective pharmacogenomics studies may be informative to further elucidate the role of genetic risk factors in drug-induced retinal toxicity.Keywords
This publication has 5 references indexed in Scilit:
- The CRB1 Complex: Following the Trail of Crumbs to a Feasible Gene Therapy StrategyFrontiers in Neuroscience, 2017
- Didanosine-Associated Retinal Toxicity in Adults Infected With Human Immunodeficiency VirusJAMA Ophthalmology, 2013
- Drug‐Drug and Drug‐Food Interactions Between Tenofovir Disoproxil Fumarate and DidanosineThe Journal of Clinical Pharmacology, 2005
- Retinal toxicity associated with didanosine in HIV-infected adultsAIDS, 1996
- Retinal Toxicity in Human Immunodeficiency Virus–infected Children Treated With 2′,3′-DideoxyinosineAmerican Journal of Ophthalmology, 1992